Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802

Clinical Pharmacokinetics

Volumn 37, Issue 6, 1999, Pages 471-484

  He, George ^a,d   Massarella, Joseph ^b   Ward, Penelope ^c  

^a Roche Global Development ^*  (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d Roche Global Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; CREATININE; DRUG METABOLITE; OSELTAMIVIR; PROBENECID; PRODRUG; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; URICOSURIC AGENT;

CREATININE CLEARANCE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; GLOMERULUS FILTRATION RATE; HUMAN; INFLUENZA; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; PRIORITY JOURNAL; REVIEW;

EID: 0033385681     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937060-00003     Document Type: Review

References (50)

1. 1. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993; 307: 982-6
2. 2. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Texthook of influenza. Oxford: Blackwell Science, 1998: 219-64
3. 3. Piedra PA. Influenza virus pneumonia: pathogenesis, treatment, and prevention. Semin Resp Infect 1995; 10: 216-23
4. 4. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998; 47 RR-6: 1-29
5. 5. Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996; 9 (3 Suppl.): 62-6
6. 6. Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993; 110: 145-60
7. 7. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza A in healthy working adults. N Engl J Med 1995; 33: 889-93
8. 8. Smith A. The socioeconomic aspects and behavioural effects of influenza. In: Wood C, editor. Influenza: strategies for Prevention. London: Royal Society of Medicine, 1988: 46-52
9. 9. Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, Knipe DM, Howley PM, editors. Straus Fields' virology. 3rd ed. Philadelphia (PA): Lippincott-Raven, 1996: 1397-445
10. 10. Laver WG, Bischofberger N, Webster RG. Disarming flu viruses. Sci Am 1999; 280 (1): 78-87
11. 11. Zimmerman RK, Ruben FL, Ahwesh ER. Influenza, influenza vaccine, and amantadine/rimantadine. J Fam Pract 1997; 45: 107-22
12. 12. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176: 119-30
13. 13. Hayden FG, Gwaltney Jr JM, van de Castle RL, et al. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother 1981; 19: 226-33
14. 14 Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580-4
15. 15. Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel prolein. Semin Virol 1992; 3: 21-30
16. 16. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303: 41-4
17. 17. Palese P, Tobita K, Ueda M, et al. Characterization of temperature sensitive influenza virus mutants. Virology 1974; 61: 397-410
18. 18. Palese P, Complans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoro-acetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976; 33: 159-63
19. 19. Liu C, Eichelberger MC, Complans RW, et al. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995; 69: 1099-106
20. 20. Klenk HD, Rott R, The molecular biology of influenza virus pathogenicity. Adv Virus Res 1988; 34: 247-80
21. 21. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418-23
22. 22. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119: 681-90
23. 23. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42: 640-6
24. 24. Hayden FG, Rollins BS. In vitro activity of the neuraminidase inhibitor GS 4071 against influenza viruses [abstract 159]. Antiviral Res 1997; 34: A86
25. 25. Hayden FG, Rollins BS, Madren I.K. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994; 25: 123-31
26. 26. Woods JM, Bethell RC, Coates JAV, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidasc (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473-9
27. 27. Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998; 37: 107-20
28. 28. Roberts NA, Carr JC, Lambkin R, et al. Oral administration of the neuraminidase inhibitor prodrug GS4104 blocks influenza virus replication in ferrets [abstract]. European Respiratory Society Annual Congress; 1998 Sep 19-23; Geneva
29. 29. Oxford JS, Roberts N, Kelly L, et al. Targeting influenza infection through neuraminidase inhibition: GS4104 activity in the ferret model [abstract]. European Society for Clinical Virology - Progress in Virology VI; 1998 Aug 30-Sept 2; Hamburg
30. 30. Sidwell RW, Burger RA, Huffman JH, et al. Immunological effects of the orally administered neuraminidase inhibitor GS4104 in influenza virus-infected and uninfected mice [abstract]. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; Sun Diego
31. 31. F. Hoffmann-La Roche Ltd, Gilead Sciences. Investigational drug brochure, oseltamivir [GS4104/Ro 640796/neuraminidase inhibitor]. F. Hoffmann-La Roche Ltd and Gilead Sciences, 1997
32. 32. Cundy KC, Eisenberg G, Bidgood A, et al. The novel influenza neuraminidase inhibitor prodrug GS4104 is highly bioavailahle in animals [abstract H123]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28-Oct 1; Toronto, 237
33. 33. Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42 (3): 647-53
34. 34. Wiltshire HR, Muir J, Lambkin R, et al. Distribution pattern of GS4071, a novel influenza neuraminidase inhibitor, following oral administration of its prodrug GS4104 in the ferret model [abstract and poster], European Society for Clinical Virology; 1998 Aug 30-Sep 2; Hamburg
35. 35. Cundy KC, Eisenberg G, Bidgood A, et al. Enhanced delivery of the novel influenza neuraminidase inhibitor GS4071 to rat lung after oral administration of the prodrug GS4104 [abstract A-122]. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto, 25
36. 36. Eisenberg EJ, Bidgood A, Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 1997; 41: 1949-52
37. 37. Wiltshire HR, Wiltshire BG. An integrated summary of the analytical methods used and data obtained during the clinical and pre-clinical development of Ro 64-0796/002. Research report W-143081, 1999. (Data on file)
38. 38. He G, Massarella J, Schulz R, et al. The absolute bioavailability of the novel oral neuraminidase inhibitor Ro 64-079/GS4104 [abstract]. American Association of Pharmaceutical Scientists, Southeast Regional Meeting; 1999 Jun 21; Durham, NC
39. 39. He G, Massarella J, Schulz R, et al. The effect of food on the pharmacokinetics of the novel oral neuraminidase inhibitor Ro 64-0796/GS4104 [abstract]. American Association of Pharmaceutical Scientists, Southeast Regional Meeting; 1999 Jun 21; Durham, NC
40. 40. Wiltshire HR. A cross-species comparison of the protein-binding and red cell partitioning of Ro 64-0796 and Ro 64-0802 (DHB08201 and DHB0802). Research report W-143012, 1998. (Data on file)
41. 41. Wiltshire HR. An investigation of the potential inhibitory effect of Ro 64-0796 and Ro 64-0802 on the metabolism of cytochrome P450 model substrates. Research report W-142919, 1998. (Data on file)
42. 42. Wood ND, Aitken M, Sharp S, et al. Tolerability and pharmacokinetics of the neuraminidase inhibitor Ro 64-0802 (GS4071) following oral administration of the prodrug Ro 64-0796 (GS4104) to healthy male volunteers [abstract A-123]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto, 25
43. 43 Algranati NE, Massarella JW, Wood ND, et al. Pharmacokinetics and tolerability of the influenza neuraminidase inhibitor Ro 64-0802 following multiple dose oral administration of the prodrug Ro 64-0796 to healthy young and elderly subjects [abstract and poster]. European Respiratory Society Annual Congress; 1998 Sep 19-23; Geneva
44. 44. He G, Massarella J, Robson R, et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor Ro 64-0796/GS4104 in subjects with renal impairment [abstract and poster]. 9th European Congress of Clinical Microbiology and Infectious Diseases; 1999 Mar 21-24; Berlin
45. 45. Grosse M. Clinical study report - protocol NP15717. Study of the PD and PK of the neuraminidase inhibitor Ro 64-0796 (GS4104) in the treatment of volunteers experimentally infected with human influenza B virus. Research report W-144105, 1999. (Data on file)
46. 46. Dorkings J. Clinical study report - protocols WV 15670, WV 15671 and WV 15730. A report on the pharmacokinetic results from the phase III studies for the neuraminidase inhibitor Ro 64-0796. Research report W-144130, 1999. (Data on file)
47. 47. He G, Massarella J, Aitken M, et al. The safety and pharmacokinetics of the neuraminidase inhibitor Ro 64-0796 when administered concurrently with paracetamol [abstract]. 9th European Congress of Clinical Microbiology and Infectious Diseases; 1999 Mar 21-24; Berlin
48. 48. He G, Massarella J, Aitken M, et al. The pharmacokinetics and safety of the oral neuraminidase inhibitor RO 64-0796/GS4104 when administered concurrently with cimetidine or probenecid in healthy subjects [abstract]. 21st International Congress of Chemotherapy, 1999 Jul 4-7; Birmingham
49. 49. Small I, Oo C, Dorr A, et al. Clinical study report - protocol NP15901. An open-label, two-way crossover, randomised pharmacokinetic drug interaction study of neuraminidase inhibitor Ro 64-0796/GS4104 and amoxicillin in healthy volunteers. Research report W-144169, 1999. (Data on file)
50. 50. He G, Massarella J, Schulz R, et al. The relative bioavailability of early clinical and market formulations of the novel oral neuraminidase inhibitor Ro 64-0796/GS4104. 2nd European Congress of Pharmacology; 1999 Jul 3-7; Budapest